Zinc Chloride
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Zinc Chloride
- Zinc Chloride: From Parenteral Trace Element Supplementation to Severe Nonproliferative Diabetic Retinopathy
Zinc Chloride: From Parenteral Trace Element Supplementation to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Zinc chloride is a trace element salt, and its registered South African products appear to be parenteral nutrition and trace element preparations. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but there are currently 0 clinical trials and 0 publications supporting this specific prediction. It rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data. Product names (Peditrace, Addaven, TPN products) suggest parenteral trace element supplementation, but this is inferred rather than registered wording |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, zinc chloride is a zinc source used in trace element and nutrition formulations, and mechanistically it may be relevant to the eye because zinc is a cofactor for antioxidant enzymes such as SOD1.
The link to diabetic retinopathy is a hypothesis only: zinc might modulate oxidative stress in the diabetic retina. Nothing in the supplied data confirms this. The similarity between the original and predicted indications has not been assessed. A high model score is not clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for severe nonproliferative diabetic retinopathy.
Literature Evidence
Currently no related literature available.
South Africa Market Information
The registration data do not include approved indication text, so that column is omitted. Only 5 of the 10 registrations were supplied.
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Y/6.1/415 | Dopamine HCl Fresenius 5 ml 200 mg/5 ml | Injection |
| 29/24/0462 | Peditrace 10 ml | Infusion |
| 49/24/0996 | Addaven | Infusion |
| ARTICLE 21B N/A | ITN 3007M 2500 ml | TPN |
| EXCLUSION UNDER SECTION 36 & SECTION 14 | ITN 55A 600 ml | TPN |
- The dopamine product is an unexpected match for a zinc salt. Verify it against its ingredient list.
- The last two entries carry no standard registration number. They appear to be special-access or exclusion entries.
- All listed forms are parenteral, so no ocular or topical product is registered.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction has no trials, no literature and no verified mechanism. Safety information is also missing, which blocks safety screening.
Other predictions in the pack:
- Sjögren syndrome (score 99.18%) has no trials or literature.
- Dry eye syndrome (score 99.18%) is the only prediction with trials, rated L4 and worth a research question. Both trials are small, completed and indirect, and no results were supplied:
- NCT02951910 is a Phase 4 trial (n=20) of zinc-hyaluronate, which is a different compound from zinc chloride.
- NCT01541891 is a Phase 2 trial (n=30) of PRO-148 versus Systane. Its composition is unconfirmed.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications. This is a blocking gap.
- Mechanism of action data, for example from DrugBank.
- A targeted literature and trial search for zinc in diabetic retinopathy.
- Confirmation of the original registered indication and of the dopamine product’s link to zinc chloride.
- An assessment of route compatibility, since all registered products are parenteral and the predicted indications are ocular.
This report is for research reference only and is not medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.